BOSTON, July 29, 2021
/PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which
recently announced a business combination with Soaring Eagle
Acquisition Corp. (Nasdaq: SRNG), is scheduled to participate in
the following upcoming conferences:
- Management will participate in one-on-one meetings and a
fireside chat at the Jefferies Virtual Industrials
Conference on Wednesday, August 4,
2021, at 10:30 a.m. Eastern
Time.
- Management will participate in one-on-one meetings and give a
presentation at the UBS Genomics 2.0 and Medtech Innovations
Summit in Laguna Beach,
California on Wednesday, August 11,
2021, at 10:00 a.m. Pacific
Time (1:00 p.m. Eastern
Time).
Live webcasts, as well as replays, of the fireside chat and
presentation will be available on the company's investor relations
website at https://www.ginkgobioworks.com/investors/.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program
cells as easily as we can program computers. The company's platform
is enabling biotechnology applications across diverse markets, from
food and agriculture to industrial chemicals to pharmaceuticals.
Ginkgo is also actively supporting a number of COVID-19 response
efforts, including K-12 pooled testing, vaccine manufacturing
optimization and therapeutics discovery. In May 2021, Ginkgo announced a business combination
with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), which, if
completed, will result in Ginkgo, through a parent entity, Ginkgo
Bioworks Holdings, Inc., becoming a public company. The transaction
is expected to close in the third quarter of 2021,
subject to regulatory and shareholder approvals, and other
customary closing conditions. For more information, visit
www.ginkgobioworks.com.
MEDIA CONTACT:
press@ginkgobioworks.com
INVESTOR CONTACT:
investors@ginkgobioworks.com
ADDITIONAL LEGAL INFORMATION
Forward-Looking Statements Legend
This document contains certain forward-looking statements within
the meaning of the federal securities laws with respect to the
proposed transaction between Ginkgo and Soaring Eagle Acquisition
Corp. ("SRNG"), including statements regarding the
benefits of the transaction, the anticipated timing of the
transaction, the services offered by Ginkgo and the markets in
which it operates, and Ginkgo's projected future results. These
forward-looking statements generally are identified by the words
"believe," "project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including but not
limited to: (i) the risk that the transaction may not be
completed in a timely manner or at all, which may adversely affect
the price of SRNG's securities, (ii) the risk that the
transaction may not be completed by SRNG's business combination
deadline and the potential failure to obtain an extension of the
business combination deadline if sought by SRNG, (iii) the
failure to satisfy the conditions to the consummation of the
transaction, including the adoption of the agreement and plan of
merger by the shareholders of SRNG and Ginkgo, the satisfaction of
the minimum trust account amount following redemptions by SRNG's
public shareholders and the receipt of certain governmental and
regulatory approvals, (iv) the lack of a third party valuation
in determining whether or not to pursue the proposed transaction,
(v) the occurrence of any event, change or other circumstance
that could give rise to the termination of the agreement and plan
of merger, (vi) the effect of the announcement or pendency of
the transaction on Ginkgo business relationships, performance, and
business generally, (vii) risks that the proposed transaction
disrupts current plans of Ginkgo and potential difficulties in
Ginkgo employee retention as a result of the proposed transaction,
(viii) the outcome of any legal proceedings that may be
instituted against Ginkgo or against SRNG related to the agreement
and plan of merger or the proposed transaction, (ix) the
ability to maintain the listing of SRNG's securities on Nasdaq,
(x) volatility in the price of SRNG's securities due to a
variety of factors, including changes in the competitive and highly
regulated industries in which Ginkgo plans to operate, variations
in performance across competitors, changes in laws and regulations
affecting Ginkgo's business and changes in the combined capital
structure, (xi) the ability to implement business plans,
forecasts, and other expectations after the completion of the
proposed transaction, and identify and realize additional
opportunities, and (xii) the risk of downturns in demand for
products using synthetic biology. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the "Risk
Factors" section of SRNG's proxy statement/prospectus relating to
the transaction, and in SRNG's other filings with the Securities
and Exchange Commission (the "SEC"). SRNG and Ginkgo
caution that the foregoing list of factors is not exclusive. SRNG
and Ginkgo caution readers not to place undue reliance upon any
forward-looking statements, which speak only as of the date made.
Neither SRNG nor Ginkgo undertake or accept any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions or circumstances
on which any such statement is based.
Additional Information and Where to Find It
This document relates to a proposed transaction between Ginkgo
and SRNG. This document does not constitute an offer to sell or
exchange, or the solicitation of an offer to buy or exchange, any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
proposed transaction, SRNG filed a registration statement on
Form S-4/A with the SEC on July
16, 2021, which included a proxy statement of SRNG and a
prospectus of SRNG. The definitive proxy statement/prospectus will
be sent to all SRNG shareholders as of the record date to be
established for voting on the proposed business combination and
Ginkgo stockholders. SRNG also will file other documents regarding
the proposed transaction with the SEC. Before making any voting
decision, investors and security holders of SRNG and Ginkgo are
urged to read the registration statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC in connection with the proposed
transaction as they become available because they will contain
important information about the proposed transaction.
Investors and security holders may obtain free copies of the
proxy statement/prospectus and all other relevant documents filed
or that will be filed with the SEC by SRNG through the website
maintained by the SEC at www.sec.gov. In addition, the documents
filed by SRNG may be obtained free of charge by written request to
SRNG at 955 Fifth Avenue, New York,
NY, 10075, Attention: Eli
Baker, Chief Financial Officer, (310) 209-7280.
Participants in Solicitation
SRNG's and Ginkgo and their respective directors and officers
may be deemed to be participants in the solicitation of proxies
from SRNG's stockholders in connection with the proposed
transaction. Information about SRNG's directors and executive
officers and their ownership of SRNG's securities is set forth in
SRNG's filings with the SEC. To the extent that holdings of SRNG's
securities have changed since the amounts printed in SRNG's proxy
statement, such changes have been or will be reflected on
Statements of Change in Ownership on Form 4 filed with the SEC.
Additional information regarding the interests of those persons and
other persons who may be deemed participants in the proposed
transaction may be obtained by reading the proxy
statement/prospectus regarding the proposed transaction when it
becomes available. You may obtain free copies of these documents as
described in the preceding paragraph.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-upcoming-conferences-301344236.html
SOURCE Ginkgo Bioworks